P-262 Response to perioperative chemotherapy in locally advanced gastric cancer

Gastric cancer was the 6th most frequent tumor worldwide in 2020. The prognosis of patients with gastric and gastrooesophageal junction (GEJ) adenocarcinoma is poor. Many efforts had been made to improve these patients’ prognosis, as adjuvant chemotherapy, chemoradiation perioperative chemotherapy. benefit overall survival (OS) disease free (DFS) chemotherapy first demonstrated MAGIC trial. FLOT trial established a superior regimen over ECF, despite that still poor high recurrence rate. authors’ aim characterize locally advanced who underwent their outcomes related factors outcomes, namely response resume post-operative pathological stage. Retrospective analysis between January 1st 2016 December 31st 2020 single hospital Portugal. Clinic-pathological characteristics were accessed by reviewing medical records. A descriptive performed. Kaplan-Meier curves Log-rank test performed for analysis, SPSS®20. total 68 included. median age 64-years-old (35-78), 69% (n=47) male, 19% (n=13) an ECOG-PS 0. As clinical stage, 10% (n=7) at stage Ib, 24% (n=16) II 38% (n=26) III. 16% (n=11) tumors GEJ. Regarding histology 57% (n=39) presented intestinal type. 54% (n=37) received FLOT; 22% (n=15) EOX, FOLFOX 7% (n=5) ECF. Surgery all patients, 59% (n=40) gastrectomy. 4% (n=3) complete preoperative minimal 43% it not reported. 85% 74% completed initial regimen. With follow-up 29 months (3-75), 35% (n=24) event (recurrence or death). estimated 48 DFS 62%, OS 67%. In our study associated (56.5 vs 10.4 months, p < 0.001) (59 13.5 .001). Patients better (61.2 40.8 months) however this increase statistical significant. Pathological outcome. Despite pathologic lymph node staging impact (ypN0 51.8 ypN3 14.9 .001) 53months 25 p=.001) Perioperative 18% experienced adverse events grade ≥3, neutropenia common, without difference regimens. No 5 occurred. Our results emphasize importance completing retrospective nature study, small sample size, and, important, low report pathology, limits assessment value